Co-located with the 6th Annual Proteins Congress & the 3rd Annual Vaccines Congress, Oxford Global are proud to present the Biosimilars & Biobetters Congress, taking place on 25th & 26th March 2013 at Novotel London West.

 

The value of the follow-on biologics market is predicted to reach $4 billion over the next five years. Our conference programme focuses on the challenges, innovations and technologies that promise to put this sector at the forefront of the pharmaceutical industry.

 

On Day 1 our internationally renowned speakers will outline their strategies for capitalising on the latest technical breakthroughs and making the most of opportunities in emerging markets. Presentations will focus on the major challenges to commercial success, including regulatory hurdles, outsourcing relationship management and decisions regarding market entry.

 

Day 2 is dedicated to a detailed discussion of the latest breakthroughs in biosimilar and biobetter development. Industry leaders will discuss strategies for demonstrating biosimilarity, identifying successful biosuperiors and utilising new technologies to combat the difficulties in protein characterisation. Delegates will learn about the critical opportunities in mAbs and Fc fusion therapeutics and hear case studies concerning immunogenicity testing and patient safety.

 

The Biosimilars & Biobetters Congress is part of the highly successful Oxford Global Proteins Series.